Professor Mikhail Kosiborod
Cardiology
Mikhail Kosiborod is a cardiologist, the Vice-President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City School of Medicine, and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System.
Professor Kosiborod is an internationally recognized expert in the field of cardiometabolic disease and has authored and co-authored more than 400 peer-reviewed publications. Professor Kosiborod has conducted and led numerous national and international clinical trials; many of which have had a significant impact on treatment guidelines and clinical practice. Professor Kosiborod’s body of work has been central to the elucidation of the impact of sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in improving cardiovascular outcomes and survival in various clinical settings, perhaps some of the most important advances in clinical cardiology seen in a generation.
Mikhail Kosiborod is a cardiologist, the Vice-President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City School of Medicine, and the inaugural recipient of the Ben McCallister, MD Endowed Chair in Cardiovascular Research at Saint Luke’s Health System.
Professor Kosiborod is an internationally recognized expert in the field of cardiometabolic disease and has authored and co-authored more than 400 peer-reviewed publications. Professor Kosiborod has conducted and led numerous national and international clinical trials; many of which have had a significant impact on treatment guidelines and clinical practice. Professor Kosiborod’s body of work has been central to the elucidation of the impact of sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in improving cardiovascular outcomes and survival in various clinical settings, perhaps some of the most important advances in clinical cardiology seen in a generation.